|
8th Annual Conference Of The British HIV Association [BHIVA]19 – 21 April 2002, University of York, York |
[AUTHOR(S):] LA Paddam1, AN Phillips1, JD Lundgren2, on behalf of EuroSIDA
1 Royal Free and University College Medical School, London, UK, and 2 CHIP, Hvidovre, Denmark
BHIVA Conf 2002 Apr 19-21;8:O1
OBJECTIVES: To describe current (most recent data since July 2000) clinical, immune and viral status of patients in EuroSIDA who started HAART, including protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors, during 1996.
METHODS: Current outcome was classified by recording whether a new AIDS event or death occurred since the start of HAART, the absolute CD4 cell count, change in the CD4 count and HIV RNA status since July 2000.
RESULTS: 2287 patients [median age 38 years, interquartile range (IQR) 33–46; 85% men] were identified as starting a HAART regimen in 1996. Most (n=2195, 96%) were on PI-containing regimens, but only 261 (11.4%) were therapy-naïve. The median CD4 cell count at entry was 101 cells/µL (IQR 37–202) and the viral load was 4.7 log10 copies/mL (3.9–5.3) in those with data available (n=1358 and 868, respectively). The median follow-up to the last clinic visit (up to April 2001) was 49 months (42–53). 287 (12.5%) patients died during follow-up. Of 1476 patients alive and followed after 1 July 2000, 267 (18.1%) had had an AIDS event. Of 1442 patients who had a CD4 cell count available after July 2000 (excluding those who died), 727 (50.5%) had >350 cells/µL. The median CD4 count change in 882 patients with baseline counts was +240 cells/µL (IQR 102–393). 1389 patients had a viral load reading after July 2000, of whom 910 (65.5%) were undetectable (<2.7 log10 copies/mL). The median viral load change in 547 patients with baseline viral load was –2.35 log10 copies/mL (IQR –1.01 to –3.35). Updated results will be presented.
CONCLUSION: EuroSIDA patients who started HAART in 1996 seem to be doing well more than 4 years later, despite most being nucleoside reverse transcriptase inhibitor-experienced at the start of HAART.
PRESENTING AUTHOR: LA Paddam
020419
O1
Copyright © 2002 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD